⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Mepolizumab

مپولیزوماب

⚠ Unverified

🌬️ Respiratory SystemAnti-IL-5 antibody

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA125526 ATC R03DX09

Market / country: 🇺🇸 USA

Nucala (US)

🧮 Dose calculator

Disease / regimen

Asthma and chronic lung disease (reversible airflow obstruction) · Regimen source: FDA Nucala · 2.1, Table 1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ History of hypersensitivity to mepolizumab. FDA Nucala · 4

Warnings

• Hypersensitivity; not for acute asthma; do not stop corticosteroids abruptly; treat helminth infection before starting. FDA Nucala · 5
• Herpes zoster (consider vaccination before starting). FDA Nucala · 5.3

Formulations

100 mg/mL prefilled syringe or autoinjector — injection 🇺🇸 USA FDA Nucala · 3
40 mg/0.4 mL prefilled syringe — injection 🇺🇸 USA FDA Nucala · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Nucala · 8.1
“Risk Summary The data on pregnancy exposure are insufficient to inform on drug-associated risk.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Nucala · 8.2
“Risk Summary There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Nucala · 8.4
“Severe Asthma The safety and effectiveness of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Nucala · 8.5
“No overall differences in safety and effectiveness were observed between these patients and younger patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA125526
DailyMed (FDA label)FDA Nucala
MedlinePlus (NIH)Mepolizumab Injection
WHO ATC/DDDR03DX09
Darooyab (Iran)Mepolizumab

🇮🇷 Registered in Iran Darooyab · G-5503/Mepolizumab

Dosage forms with Iranian generic codes, per Darooyab.

50765 · MEPOLIZOMAB INJECTION, POWDER, FOR SOLUTION PARENTERAL 100 mg · پودر برای تهیه محلول تزریقی مپولیزومب ۱۰۰ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Nucala · 3 FDA Nucala · 2.1, Table 1 FDA Nucala · 2.1 FDA Nucala · 4 FDA Nucala · 5 FDA Nucala · 5.3 FDA Nucala · SPL approval / marketing category FDA Nucala · 8.1 FDA Nucala · 8.2 FDA Nucala · 8.4 FDA Nucala · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-5503/Mepolizumab
Clinical review⚠ Unverified